Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study

Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new...

Marvel Biosciences Announces Proposed Debenture Offering

Calgary, Alberta – Marvel Biosciences Corp. (“Marvel” or the “Company”) announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures (“Debentures”) in the principal amount of up to...